Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
<Bundle xmlns="http://hl7.org/fhir">
<id value="bundlepackageleaflet-en-1a455c95e5d54239c06a46b5802914f3"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
</meta>
<language value="en"/>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="None"/>
</identifier>
<type value="document"/>
<timestamp value="2023-06-27T10:09:22Z"/>
<entry>
<fullUrl
value="Composition/composition-en-1a455c95e5d54239c06a46b5802914f3"/>
<resource>
<Composition>
<id value="composition-en-1a455c95e5d54239c06a46b5802914f3"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
</meta>
<language value="en"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><a name="Composition_composition-en-1a455c95e5d54239c06a46b5802914f3"> </a><p class="res-header-id"><b>Generated Narrative: Composition composition-en-1a455c95e5d54239c06a46b5802914f3</b></p><a name="composition-en-1a455c95e5d54239c06a46b5802914f3"> </a><a name="hccomposition-en-1a455c95e5d54239c06a46b5802914f3"> </a><a name="composition-en-1a455c95e5d54239c06a46b5802914f3-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Language: en</p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/14/983/001</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}">Package Leaflet</span></p><p><b>category</b>: <span title="Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href="Organization-mah-ema.html">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - exviera</p><h3>Attesters</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/composition-attestation-mode official}">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/14/983/001"/>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package Leaflet"/>
</type>
<category>
<coding>
<system
value="http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"/>
<code value="R"/>
<display value="Raw"/>
</coding>
</category>
<subject>
<reference
value="MedicinalProductDefinition/mp1a455c95e5d54239c06a46b5802914f3"/>
</subject>
<date value="2022-02-16T13:28:17Z"/>
<author>🔗
<reference value="Organization/mah-ema"/>
</author>
<title value="TEST PURPOSES ONLY - exviera"/>
<attester>
<mode>
<coding>
<system
value="http://hl7.org/fhir/composition-attestation-mode"/>
<code value="official"/>
</coding>
</mode>
<time value="2022-02-16T13:28:17Z"/>
</attester>
<section>
<title value="B. Package Leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="B. Package Leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="unavailable"/>
</coding>
</emptyReason>
<section>
<title value="Package leaflet: Information for the user"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package leaflet: Information for the user"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"></div>
</text>
</section>
<section>
<title value="What is in this leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="What is in this leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What is in this leaflet</p><ol type="1"><li>What Exviera is and what it is used for</li><li>What you need to know before you take Exviera</li><li>How to take Exviera</li><li>Possible side effects</li><li>How to store Exviera</li><li>Contents of the pack and other information</li></ol></div>
</text>
</section>
<section>
<title value="1. What exviera is and what it is used for"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="1. What exviera is and what it is used for"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Exviera contains the active substance dasabuvir. Exviera is an antiviral medicine used to treat adults with chronic (long-term) hepatitis C (an infectious disease that affects the liver, caused by the hepatitis C virus). Exviera works by stopping the hepatitis C virus from multiplying and infecting new cells, thus clearing the virus from your blood over a period of time. Exviera tablets do not work on their own. They are always taken with another antiviral medicine containing ombitasvir/paritaprevir/ritonavir. Some patients may also take an antiviral medicine called ribavirin. Your doctor will talk with you about which of these medicines to take with Exviera. It is very important that you also read the package leaflets for the other antiviral medicines that you take with Exviera. If you have any questions about your medicines, please ask your doctor or pharmacist.</p></div>
</text>
</section>
<section>
<title value="2. What you need to know before you take exviera"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="2. What you need to know before you take exviera"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Do not take Exviera:</p><p>If you are allergic to dasabuvir or any of the other ingredients of this medicine (listed in section 6).</p><p>If you have moderate to severe liver problems other than hepatitis C.</p><p>If you are taking any of the medicines listed in the following table. This is because serious or life- threatening effects can occur when Exviera and ombitasvir/paritaprevir/ritonavir are taken with these medicines. These medicines can affect the way Exviera and ombitasvir/paritaprevir/ritonavir work and Exviera and ombitasvir/paritaprevir/ritonavir can affect the way these other medicines work. Medicines you must not take with Exviera Medicine or active substance Purpose of the medicine carbamazepine, phenytoin, phenobarbital for epilepsy efavirenz, etravirine, nevirapine for HIV infection Apalutamide, enzalutamide for prostate cancer ethinyloestradiol containing medicines such as those contained in most contraceptive pills and vaginal rings used for contraception for contraception gemfibrozil to lower cholesterol and other fats in the blood mitotane for some tumours of the adrenal glands rifampicin for bacterial infections St. John s Wort (hypericum perforatum) a herbal medicine for anxiety and mild depression. This medicine is available without a prescription Do not take Exviera if any of the above apply to you. If you are not sure, talk to your doctor or pharmacist before taking Exviera. Warnings and precautions Talk to your doctor or pharmacist before taking Exviera if you:</p><ul><li><p>have liver disease other than hepatitis C;</p></li><li><p>have a current or previous infection with the hepatitis B virus, since your doctor may want to monitor you more closely.</p></li><li><p>have diabetes. You may need closer monitoring of your blood glucose levels and/or adjustment of your diabetes medicines after starting Exviera. Some diabetic patients have experienced low sugar levels in the blood (hypoglycaemia) after starting treatment with medicines like Exviera. When taking Exviera and ombitasvir/paritaprevir/ritonavir, tell your doctor if you have the following symptoms as they may be a sign of worsening liver problems:</p></li><li><p>Feel sick (nauseous), are sick (vomit) or lose your appetite.</p></li><li><p>Notice yellowing of your skin or eyes.</p></li><li><p>Your urine is darker than normal.</p></li><li><p>Confusion</p></li><li><p>Notice swelling of your stomach area If any of the above apply to you (or you are not sure), talk to your doctor or pharmacist before taking Exviera. Tell your doctor if you have a history of depression or psychiatric illness. Depression, including suicidal thoughts and behaviours, has been reported in some patients taking this medicine, particularly in patients with a prior history of depression or psychiatric illness or in patients taking ribavirin with this medicine. You or your caregiver should also immediately inform your doctor of any changes in behaviour or mood and of any suicidal thoughts you may have. Blood tests Your doctor will test your blood before, during and after your treatment with Exviera. This is so that your doctor can:</p></li></ul><p>Decide what other medicines you should take with Exviera and for how long.</p><p>Confirm if your treatment has worked and if you are free of the hepatitis C virus.</p><p>Check for side effects of Exviera or other antiviral medicines your doctor has prescribed for you to use with Exviera (such as ombitasvir/paritaprevir/ritonavir and ribavirin ). Children and adolescents Do not give Exviera to children and adolescents under 18 years of age. The use of Exviera in children and adolescents has not yet been studied. Other medicines and Exviera Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. There are some medicines you must not take with Exviera - see the previous table Medicines you must not take with Exviera . Tell your doctor or pharmacist before taking Exviera, if you are taking any of the medicines in the table below. The doctor may need to change your dose of these medicines. Tell your doctor or pharmacist before taking Exviera if you are also using hormonal contraceptives. See the section on contraception below. Medicines you must tell your doctor about before taking Exviera Medicine or active substance Purpose of the medicine alprazolam, diazepam for anxiety, panic attacks and trouble sleeping ciclosporin, everolimus, sirolimus, tacrolimus to suppress the immune system cyclobenzaprine, carisoprodol for muscle spasms dabigatran to thin the blood deferasirox to help reduce iron levels in the blood digoxin, amlodipine for heart problems or high blood pressure furosemide for the build-up of too much fluid in the body hydrocodone for pain imatinib for the treatment of some cancers of the blood levothyroxine for thyroid problems darunavir/ritonavir, atazanavir/ritonavir, rilpivirine for HIV infection omeprazole, lansoprazole, esomeprazole for stomach ulcers and other stomach problems rosuvastatin, pravastatin, fluvastatin, pitavastatin to lower blood cholesterol s-mephenytoin for epilepsy teriflunomide for multiple sclerosis sulfasalazine to treat and manage inflammatory bowel disease or to treat rheumatoid arthritis warfarin and other similar medicines called vitamin K antagonists* to thin the blood *Your doctor may need to increase the frequency of your blood tests to check how well your blood can clot. If any of the above apply to you (or you are not sure), talk to your doctor or pharmacist before taking Exviera. Pregnancy and contraception The effects of Exviera during pregnancy are not known. Exviera should not be used during pregnancy or in women of childbearing potential not using effective contraception.</p><p>You or your partner must use an effective method of contraception during treatment. Contraceptive medicines that contains ethinyloestradiol cannot be used in combination with Exviera. Ask your doctor about the best contraception for you. Extra precautions are needed if Exviera is taken together with ribavirin. Ribavirin may cause severe birth defects. Ribavirin stays for a long time in the body after treatment is stopped, and effective contraception is therefore needed both during treatment and for some time afterwards. There is a risk for birth defects when ribavirin is given to a female patient that becomes pregnant. There may also be a risk for birth defects if ribavirin is taken by a male patient, whose female partner becomes pregnant. Read the Contraception section of the package leaflet for ribavirin very carefully. It is important that both men and women read the information. If you or your partner becomes pregnant during treatment with Exviera and ribavirin or in the months that follow, you must contact your doctor immediately. Breastfeeding You should not breastfeed during treatment with Exviera. It is not known whether the active substance in Exviera (dasabuvir), passes into breast milk. Driving and using machines Some patients have reported feeling very tired when taking Exviera with other medicines for their hepatitis C infection. If you feel tired, do not drive or use any machines. Exviera contains lactose If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p></div>
</text>
</section>
<section>
<title value="3. How to take exviera"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="3. How to take exviera"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. Exviera tablets do not work on their own. They are always taken with other antiviral medicines such as ombitasvir/paritaprevir/ritonavir. Your doctor may also give you an antiviral medicine called ribavirin. How much to take The recommended dose is one tablet, twice a day. Take one tablet in the morning and one tablet in the evening. How to take</p><p>Take the tablets with food. The type of food is not important.</p><p>Swallow the tablets whole with water.</p><p>Do not chew, crush or break the tablets as they may have a bitter taste. How long to take Exviera for You will take Exviera for 8, 12 or 24 weeks. Your doctor will tell you how long your treatment will last. Do not stop taking Exviera unless your doctor tells you to. It is very important that you complete the full course of treatment. This will give the medicines the best chance to clear the hepatitis C virus infection. If you take more Exviera than you should If you accidentally take more than the recommended dose, you should contact your doctor or go to the nearest hospital straight away. Keep the medicine pack with you so you can easily describe what you have taken. If you forget to take Exviera It is important not to miss a dose of this medicine. If you do miss a dose and it is:</p><p>More than 6 hours until your next dose - take the missed dose with food as soon as possible.</p><p>Less than 6 hours until your next dose - do not take the missed dose, take your next dose as usual with food. Do not take a double dose to make up for a forgotten dose. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p></div>
</text>
</section>
<section>
<title value="4. Possible side effects"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="4. Possible side effects"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Stop taking Exviera and talk to your doctor or get medical help immediately if any of the following occur: Side effects when taking Exviera with ombitasvir/paritaprevir/ritonavir with or without ribavirin: Frequency not known: cannot be estimated based on available data</p><p>Serious allergic reactions, signs may include:* Difficulty breathing or swallowing* Dizziness or light-headedness, which may be due to low blood pressure* Swelling of the face, lips, tongue or throat* Rash and itching of the skin</p><p>Worsening liver problems. Symptoms include:* Feel sick (nauseous), are sick (vomit) or lose your appetite* Notice yellowing of your skin or eyes* Your urine is darker than normal * Confusion* Notice swelling of your stomach area Tell your doctor or pharmacist if you notice any of the following side effects: Side effects when taking Exviera with ombitasvir/paritaprevir/ritonavir: Common: may affect up to 1 in 10 people</p><p>Itching. Rare: may affect up to 1 in 1,000 people</p><p>Swelling of the layers of skin which can affect any part of the body including the face, tongue or throat and may cause difficulty swallowing or breathing (angioedema) Side effects when taking Exviera and ombitasvir/paritaprevir/ritonavir with ribavirin: Very common: may affect more than 1 in 10 people</p><p>Feeling very tired (fatigue)</p><p>Feeling sick (nausea)</p><p>Itching</p><p>Trouble sleeping (insomnia)</p><p>Feeling weak or lack of energy (asthenia).</p><p>Diarrhoea Common: may affect up to 1 in 10 people</p><p>Anaemia (low number of red blood cells).</p><p>Vomiting Uncommon: may affect up to 1 in 100 people</p><p>Dehydration Rare: may affect up to 1 in 1,000 people</p><p>Swelling of the layers of skin which can affect any part of the body including the face, tongue or throat and may cause difficulty swallowing or breathing (angioedema) Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>
</text>
</section>
<section>
<title value="5. How to store exviera"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="5. How to store exviera"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Keep this medicine out of the sight and reach of children. Do not use the medicine after the expiry date which is stated on the carton after EXP . The expiry date refers to the last day of that month. This medicine does not require any special storage conditions. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p></div>
</text>
</section>
<section>
<title value="6. Contents of the pack and other information"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="6. Contents of the pack and other information"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What Exviera contains</p><p>Each tablet contains 250 mg of dasabuvir (as sodium monohydrate).</p><p>The other ingredients are:</p><p>Tablet core: microcrystalline cellulose (E 460(i)), lactose monohydrate, copovidone, croscarmellose sodium, colloidal anhydrous silica (E 551), magnesium stearate (E 470b).</p><p>Tablet film-coating: poly(vinyl alcohol) (E 1203), titanium dioxide (E 171), macrogol (3350), talc (E 553b), iron oxide yellow (E 172), iron oxide red (E 172) and iron oxide black (E 172). What Exviera looks like and contents of the pack Exviera tablets are beige, ovaloid film-coated tablets, of dimensions of 14.0 mm x 8.0 mm, marked with AV2 . Exviera tablets are packed into foil blisters containing 2 tablets. Each carton contains tablets (multipack carton containing 4 inner cartons of 14 tablets). Marketing Authorisation Holder and Manufacturer AbbVie Deutschland GmbH & Co. KG Knollstrasse 67061 Ludwigshafen Germany For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder: Belgi /Belgique/Belgien AbbVie SA T l/Tel: +32 10 477Lietuva AbbVie UAB Tel: +370 5 205 3</p><p>.: +359 2 90 30 Luxembourg/Luxemburg AbbVie SA Belgique/Belgien T l/Tel: +32 10 477 esk republika AbbVie s.r.o. Tel: +420 233 098 Magyarorsz g AbbVie Kft. Tel.: +36 1 455 8Danmark AbbVie A/S Tlf: +45 72 30-20-Malta V.J.Salomone Pharma Limited Tel: +356 22983Deutschland AbbVie Deutschland GmbH & Co. KG Tel: 00800 222843 33 (geb hrenfrei) Tel: +49 (0) 611 / 1720-0 Nederland AbbVie B.V. Tel: +31 (0)88 322 2Eesti AbbVie O Tel: +372 623 1Norge AbbVie AS Tlf: +47 67 81 80<br/>AbbVie . . : +30 214 4165 sterreich AbbVie GmbH Tel: +43 1 20589-0 Espa a AbbVie Spain, S.L.U. Tel: +34 91 384 09 Polska AbbVie Sp. z o.o. Tel.: +48 22 372 78 France AbbVie T l: +33 (0)1 45 60 13 Portugal AbbVie, Lda. Tel: +351 (0)21 1908Hrvatska AbbVie d.o.o. Tel: +385 (0)1 5625 Rom nia AbbVie S.R.L. Tel: +40 21 529 30 Ireland AbbVie Limited Tel: +353 (0)1 4287Slovenija AbbVie Biofarmacevtska dru ba d.o.o. Tel: +386 (1)32 08 sland Vistor hf. Tel: +354 535 7Slovensk republika AbbVie s.r.o. Tel: +421 2 5050 0Italia AbbVie S.r.l. Tel: +39 06 928Suomi/Finland AbbVie Oy Puh/Tel: +358 (0)10 2411<br/>Lifepharma (Z.A.M.) Ltd : +357 22 34 74 Sverige AbbVie AB Tel: +46 (0)8 684 44 Latvija AbbVie SIA Tel: +371 67605United Kingdom (Northern Ireland) AbbVie Deutschland GmbH & Co. KG Tel: +44 (0)1628 561This leaflet was last revised in Other sources of information Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>
</text>
</section>
</section>
</Composition>
</resource>
</entry>
<entry>
<fullUrl
value="MedicinalProductDefinition/mp1a455c95e5d54239c06a46b5802914f3"/>
<resource>
<MedicinalProductDefinition>
<id value="mp1a455c95e5d54239c06a46b5802914f3"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="MedicinalProductDefinition_mp1a455c95e5d54239c06a46b5802914f3"> </a><p class="res-header-id"><b>Generated Narrative: MedicinalProductDefinition mp1a455c95e5d54239c06a46b5802914f3</b></p><a name="mp1a455c95e5d54239c06a46b5802914f3"> </a><a name="hcmp1a455c95e5d54239c06a46b5802914f3"> </a><a name="mp1a455c95e5d54239c06a46b5802914f3-en-US"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/14/983/001</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}">Medicinal Product</span></p><p><b>domain</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-domain Human}">Human use</span></p><p><b>status</b>: <span title="Codes:{http://hl7.org/fhir/publication-status active}">active</span></p><p><b>legalStatusOfSupply</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi 100000072084}">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Exviera 250 mg film-coated tablets</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:ietf:bcp:47 en}">en</span></td></tr></table></blockquote></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/14/983/001"/>
</identifier>
<type>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-type"/>
<code value="MedicinalProduct"/>
<display value="Medicinal Product"/>
</coding>
</type>
<domain>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-domain"/>
<code value="Human"/>
<display value="Human use"/>
</coding>
</domain>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
<display value="active"/>
</coding>
</status>
<legalStatusOfSupply>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000072084"/>
<display
value="Medicinal product subject to medical prescription"/>
</coding>
</legalStatusOfSupply>
<name>
<productName value="Exviera 250 mg film-coated tablets"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000001"/>
<display value="Full name"/>
</coding>
</type>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000002"/>
<display value="Invented name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000003"/>
<display value="Scientific name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000004"/>
<display value="Strength part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000005"/>
<display value="Pharmaceutical dose form part"/>
</coding>
</type>
</part>
<usage>
<country>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</country>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</jurisdiction>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="en"/>
</coding>
</language>
</usage>
</name>
</MedicinalProductDefinition>
</resource>
</entry>
</Bundle>
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
